LOTEMAX SM
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LOTEMAX SM (LOTEMAX SM).
Loteprednol etabonate is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to inhibit inflammatory mediators such as prostaglandins and leukotrienes.
| Metabolism | Metabolized primarily in the eye via esterases; systemic metabolism is minimal. |
| Excretion | Renal (approximately 70% as metabolites), fecal (approximately 30% as metabolites). Less than 1% excreted unchanged. |
| Half-life | Terminal elimination half-life is approximately 8-10 hours in healthy subjects, allowing once-daily or twice-daily dosing based on severity of inflammation. |
| Protein binding | Approximately 50-70% bound to plasma proteins, primarily albumin. Binding is saturable at high concentrations. |
| Volume of Distribution | 0.5-0.7 L/kg, indicating distribution into extracellular fluid and some tissue penetration, but limited deep tissue distribution due to ocular administration. |
| Bioavailability | Ophthalmic (eye drops): Systemic absorption is minimal due to small dose and extensive metabolism; estimated absolute ocular bioavailability is not determined, but systemic bioavailability is <1% after topical administration. |
| Onset of Action | Ophthalmic: Therapeutic effect (reduction of inflammation) begins within 24 hours after instillation, with maximal effect seen within 3-7 days. |
| Duration of Action | Clinical anti-inflammatory effect persists for 8-12 hours after a single dose, supporting twice-daily dosing. Duration may be prolonged with once-daily dosing after initial control. |
| Molecular Weight | 412.9 |
One drop of 0.5% ophthalmic suspension into the affected eye(s) 4 times daily. For severe inflammation, may be increased to one drop every hour during the first week, then taper.
| Dosage form | GEL |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | Safety and efficacy in pediatric patients have not been established. Use is not recommended unless potential benefit outweighs risk. |
| Geriatric use | No overall differences in safety or efficacy observed between elderly and younger patients; use same dosing as adults. |
| 1st trimester | No adequate well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk to fetus. Corticosteroids may increase risk of oral clefts when used in first trimester. |
| 2nd trimester | Use only if clearly needed. Chronic maternal use may cause fetal growth restriction and adrenal suppression. |
| 3rd trimester | Prolonged use may lead to neonatal adrenal suppression. Avoid chronic use near term. |
Clinical note
Comprehensive clinical and safety monograph for LOTEMAX SM (LOTEMAX SM).
| Placental transfer | Limited data for ophthalmic route. Systemic corticosteroids cross the placenta. Ocular doses produce low systemic levels, so placental transfer is minimal. |
| Breastfeeding | Topical ocular administration results in negligible systemic absorption. However, corticosteroids are excreted in breast milk in amounts not expected to cause adverse effects in infants. Caution if high doses or prolonged treatment used. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Hypersensitivity to loteprednol or any component of the formulationMost viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicellaOcular fungal infectionsUntreated ocular bacterial infectionsMycobacterial eye infections
| Precautions | Prolonged use may lead to elevated intraocular pressure (IOP) and glaucoma, Risk of cataract formation with extended use, May delay wound healing and increase risk of secondary infections, Use cautiously in patients with herpes simplex keratitis, Avoid abrupt discontinuation after prolonged therapy |
| Food/Dietary | None reported. No dietary restrictions are necessary when using loteprednol etabonate ophthalmic suspension. |
Loading safety data…
| Lactation Rating | L2 (Probably Compatible) |
| Teratogenic Risk | Corticosteroids, including loteprednol etabonate, are generally considered low risk for major malformations. However, systemic use in first trimester has been associated with a small increased risk of oral clefts (odds ratio ~1.3-1.6). Topical ophthalmic use results in minimal systemic absorption, making significant teratogenic effects unlikely. No adequate well-controlled studies in pregnant women; use only if potential benefit justifies risk. |
| Fetal Monitoring | No specific monitoring required beyond usual obstetric care. If used long-term or at high doses, monitor for maternal blood glucose and blood pressure. For fetus, standard growth and development assessments. |
| Fertility Effects | No known effects on fertility from topical ophthalmic use. Systemic corticosteroids may impact ovulation or spermatogenesis at high doses, but with ophthalmic route, systemic exposure is minimal. |
| Clinical Pearls | Lotemax SM (loteprednol etabonate 0.5% ophthalmic suspension) is a corticosteroid indicated for postoperative inflammation and pain. The 'SM' formulation (superior material) offers improved drug delivery with smaller particle size, enhancing corneal permeation. Use with caution in patients with glaucoma due to potential IOP elevation; monitor IOP within 2-4 weeks. Avoid in active viral (e.g., herpes simplex), fungal, or untreated bacterial infections. Do not taper; abrupt cessation is typically safe for short-term use. |
| Patient Advice | Shake the bottle well before each use to ensure uniform suspension. · Wash hands before and after administration to prevent contamination. · Do not touch the dropper tip to any surface, including your eye, to avoid infection. · Remove contact lenses before use and wait at least 15 minutes before reinserting; do not wear while using this medication unless directed. · Use exactly as prescribed; do not use more often or longer than instructed, as prolonged use may increase risk of side effects. · If you have glaucoma, you will need regular eye pressure checks during treatment. · Report any blurred vision, eye pain, or visual changes to your doctor immediately. · Do not share this medication with others even if they have similar symptoms. |